Recent Updates
Recently added Catalysts
APLM Positive Sentiment

Apollomics Announces $10 Million Private Placement Transaction

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Apollomics Inc. has announced a $10 million private placement transaction aimed at advancing its late-stage clinical development of oncology drug candidates. The funding will support the company's efforts to tackle difficult-to-treat and treatment-resistant cancers. This financial boost is expected to enhance Apollomics' capabilities in the biopharmaceutical sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Apollomics secures $10 million in funding.
  • Funding supports development of oncology drug candidates.
  • Company focuses on addressing treatment-resistant cancers.

Full Press Release Details

FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it

Frequently Asked Questions

What is the amount of funding Apollomics secured?

Apollomics secured $10 million in a private placement transaction.

What is the focus of Apollomics' drug development?

Apollomics focuses on developing oncology drug candidates for difficult-to-treat cancers.

What type of company is Apollomics?

Apollomics is a late-stage clinical biopharmaceutical company.

ShareAdd on Google
Tags: APLM Viatris Investor Conferences Healthcare Apollomics oncology private placement cancer treatments
Last updated: Aug 11, 2026

Biotech snapshot

Lead asset
APL-101Phase 2
Solid Tumors →